Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis

Yuan Zhang; Lufei Zhang; Sinan Lu; Yucheng Xiang; Cheng Zeng; Tianyu He; Yuan Ding; Weilin Wang

doi:10.4143/crt.2020.192

Articles

Page Path: HOME > Cancer Res Treat > Volume 53(1); 2021 > Article

Original Article Gastrointestinal cancer Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis: Yuan Zhang^1,2,3,4,5, Lufei Zhang^1,2,3,4,5, Sinan Lu^1,2,3,4,5, Yucheng Xiang^1,2,3,4,5, Cheng Zeng^1,2,3,4,5, Tianyu He^2,3,4,5, Yuan Ding^1,2,3,4,5, Weilin Wang^1,2,3,4,5; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2021;53(1):184-198.
DOI: https://doi.org/10.4143/crt.2020.192
Published online: October 5, 2020

¹Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

²Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, China

³Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou, China

⁴Clinical Medicine Innovation Center of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Disease of Zhejiang University, Hangzhou, China

⁵Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, China

Correspondence: Weilin Wang, Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang 310009, China,
Tel: 86-0571-87783820, Fax: 86-0571-87068001, E-mail: wam@zju.edu.cn

* Yuan Zhang and Lufei Zhang contributed equally to this work.

• Received: March 6, 2020 • Accepted: September 15, 2020

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

7,623 Views
178 Download
15 Web of Science
15 Crossref
16 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Intrahepatic cholangiocarcinoma (ICC) is one of the most common liver primary tumors but its treatments are limited. Bioinformatics showed that the expression level of long non-coding RNA cancer-associated susceptibility 15 gene (CASC15) is correlated with ICC progression, but its functional mechanism remains unclear.
Materials and Methods
Tissues from ICC patients, tumor and adjacent tissue, were used for detection of the expression of CASC15. Clinical data were also collected for clinicopathologic and survival analysis. Short interfering RNA and lentiviral short hairpin RNA were used to knock down CASC15 and PRDX2 expression in ICC cell lines, for the analysis of changes of cell function and xenografts. RNA-pulldown and RNA immunoprecipitation assays were used to detect RNA-binding protein, PRDX2. Male nude mice were used for ICC xenografts, and livers were collected after 4 weeks for immunohistochemistry.
Results
CASC15 is highly expressed in ICC tissues and is related to higher TNM stage. Knockdown of CASC15 in ICC cells reduced cell proliferation, migration, invasiveness and increased apoptosis, and G1/S block. PRDX2 bound to CASC15. Knockdown of CASC15 decreased PRDX2 expression which was rescued by the inhibition of proteasome formation. Downregulation of PRDX2 resulted in G1/S block, reduced ICC cell invasion. Downregulation of CASC15 inhibited phosphoinositide 3-kinase (PI3K)/AKT/c-Myc pathway through downregulating of PRDX2 and overexpressed PRDX2 rescued the block. CASC15 knockout in ICC xenografts suppressed tumor development in vivo, decreased the expression of PRDX2 and Ki67 and inhibited PI3K/AKT pathway.
Conclusion
CASC15 promotes ICC possibly by targeting PRDX2 via the PI3K/AKT pathway, indicating poor prognosis and high degree of malignancy of ICC.
Key words: Long non-coding RNA, CASC15, Intrahepatic cholangiocarcinoma, PRDX2

Introduction

Cholangiocarcinoma is a type of cancer originating from biliary epithelial cells and is classified as intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma, and hilar cholangiocarcinoma according to its anatomical position [1,2]. Although cholangiocarcinoma is rare cancer, its morbidity and mortality have increased rapidly worldwide in recent decades. ICC accounts for approximately 10% of all cholangiocarcinomas and its malignancy degree is second only to hepatocellular carcinoma in primary liver cancer. Currently, the only choice for ICC treatment is surgery. However, only 15% of patients with ICC undergo surgery. Additionally, the overall survival time for patients with ICC after diagnosis is only 6–24 months, and the morbidity and mortality of ICC are nearly the same, after surgery, the median survival time of patients with ICC ranges from 27 to 36 months [2–4]. Few studies have evaluated the mechanisms of the poor prognosis of ICC or described reliable biomarkers for ICC. Thus, further investigations are urgently needed.

Many studies have shown that most (70%) of the genome is transcribed into long non-coding RNA (lncRNA) [5,6]. LncRNA is a long RNA (> 200 nucleotides) lacking a functional open reading frame and does not encode proteins. LncRNAs are classified into five categories based on their locations in the transcript: sense, antisense, bidirectional, intronic, and intergenic. Many lncRNAs have been studied because of their impact on diseases, particularly cancer. For example, lncRNA-HOX transcript antisense RNA promotes prostate cancer [7], lncRNA-retinoic acid receptor-related orphan receptor (ROR) predicts poor prognosis in pancreatic cancer [8]. Although lncRNA plays an important role in gene regulation, studies of lncRNA are limited. Cancer-associated susceptibility 15 gene (CASC15) is a newly discovered lncRNA which located at 6p22.3. Our previous study reported that CASC15 plays an important role as an oncogene in hepatocellular carcinoma [9]. Recent studies have reported that CASC15 may have an influence on ICC by promoting an inflammatory microenvironment [10,11]. However, the other mechanism of CASC15 in ICC remains unclear.

Peroxiredoxin 2 (PRDX2) is a member of the peroxiredoxin family, which is a large family of antioxidant enzymes that act as antioxidants in cells [12]. PRDX2 has been reported to function in cancer cells by regulating H₂O₂-dependent signaling [13] and reactive oxygen species-related signaling pathways [14]. Recent studies showed that PRDX2 is highly expressed in many cancers and plays a protective role in lung cancer [15], breast cancer [16], and esophagus cancer [17]. Thus, PRDX2 is a key protein in cancer cell proliferation, invasion, and apoptosis. A previous study showed that PRDX2 might function in cancer by inducing phosphoinositide 3-kinase (PI3K)/AKT pathway [18]. However, the function and functional mechanism of PRDX2 in ICC remains unclear. Thus, we focused on the relationship between lncRNA-CASC15 and PRDX2 to explore the mechanism of these two important molecules in ICC.

Materials and Methods

1. Tissues and cell lines

ICC tissue and para-carcinoma tissue were provided by the Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province. These tissues were collected from patients with hepatectomy in 2013–2016 at Medicine School of Zhejiang University, and pathological examination confirmed the diagnosis of ICC. Clinical data were all collected for clinicopathologic and survival analysis. Tissues were stored at −80°C. ICC cell lines (CCLP, RBE, 9810, and HuCCT1) were provided by the Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province. Cells were grown in Roswell Park Memorial Institute 1640 (9810, RBE, and CCLP) and Dulbecco’s modified Eagle’s medium (HuCCT1, Biological Industries, Cromwell, CT) containing 10% fetal bovine serum (FBS), purchased from Thermo Fisher Scientific (Waltham, MA). Cells were cultured at 37°C in a 5% CO₂ incubator.

2. RNA extraction and quantitative polymerase chain reaction

We used TRIzol reagent (Thermo Fisher Scientific) for the extraction of total RNA from the tissues and cells. NanoDrop ND-1000 UV/visible photometer (Thermo Fisher Scientific) was used to assess RNA purity. We used a real-time PCR instrument (Bio-Rad, Hercules, CA) to evaluate the relative expression of CASC15. Primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; F: 5′-CGGAGTCAACGGA-TTTGGTCGTAT-3′, R: 5′-AGCCTTCTCCATGGTGGTGAAGAC-3′) and CASC15 (F: 5′-CACACGCATGGAAAACCC-AG-3′, R: 5′-GAGGACCTGAGCTGTAAGCC-3′) were designed by and purchased from Shanghai Biological Engineering Technology Co. (Shanghai, China). Primers for PRDX2 (H-prdx2-S: 5′-TAATGATTTGCCTGTGGGACG-3′; H-prdx2-A: 5′-CGTTGGGCTTAATCGTGTCA-3′) were designed by Wuhan Servicebio Co. (Wuhan, China).

3. Western blotting

Proteins were extracted by radioimmunoprecipitation assay (Biyuntian Biotechnology Co., Shanghai, China) with 1% phenylmethylsulfonyl fluoride and 1% phosphate inhibitor. Proteins were fractionated in 3-morpholinopropane-1-sulfonic acid/sodium dodecyl sulfate running buffer (Thermo Fisher Scientific) with a protein electrophoresis meter (Bio-Rad) and transferred to poly(vinylidene) fluoride membranes (Bio-Rad) with a Trans-Blot (Bio-Rad). The antibodies used were GAPDH (ab9485, Abcam, Cambridge, UK), caspase-8 (ab32397, Abcam), poly(adenosine diphosphate-ribose) polymerase (PARP) (ab32064, Abcam), BAX (ab32503, Abcam), cyclin E1 (ab33911, Abcam), cyclin D1 (ab134175, Abcam), cyclin B1 (ab32053, Abcam), CDK4 (ab108357, Abcam), CDK6 (ab124821, Abcam), p21 (ab109520, Abcam), N-cadherin (ab18203, Abcam), E-cadherin (ab15148, Abcam), PI3 kinase p110α (4255S, Cell Signaling Technology, Danvers, MA), AKT (9272S, CST), phospho-AKT (Ser473) (4060S, Cell Signaling Technology), c-Myc (9402S, Cell Signaling Technology), phospho-c-Myc (Ser62) (13748S, Cell Signaling Technology), and PRDX2 (10545-2-AP, Proteintech, Rocky Hill, NJ). We used GAPDH as an internal reference.

4. Cell interference, transfection, and infection

Cells were cultured in 6-well plates with 5 μL siRNA and 5 μL Lipofectamine 2000 (Thermo Fisher Scientific) for 6 hours. The short interfering RNA (siRNA) named as RiboTM h-CASC15 Smart Silencer was provided by Guangzhou Ruibo Biological Co. (Guangzhou, China) and had the following sequences: 5′-CCCTCAGGTGACTACAGAT-3′, 5′-GCTCAA-CCACATCTAATTT-3′, 5′-GCAACATGCTTCACTGTCT-3′, 5′-GATCGCTGGGAATTCTCCAC-3′, 5′-TCAGAGCTGGCTG-CCTGACA-3′, 5′-GCCAAGAAGAGTATGCAGAG-3′. SiRNAs named as PRDX2(h)-si-1,2,3 were provided by Guannan Biological Co. (Hangzhou, China; PRDX2(h)-si-1: AGA-UCAUCGCGUUCAGCAA tt, UUGCUGAACGCGAUGA-UCU tt; PRDX2(h)-si-2: ACCCUCUGGACUUCACUUU tt, AAAGUGAAGUCCAGAGGGU tt; PRDX2(h)-si-3: GACAGCAAGGAAUAUUUCU tt, AGAAAUAUUCCUUGCUG-UC tt).

Cells were cultured in 6-well plates with 1 μg plasmid PRDX2 and 3 μL Polyjet reagent (SignaGen, Shandong, China) for 24 hours. The plasmid PRDX2 was provided by Vigen Biosciences (Shandong, China).

The cells were cultured in 6-well plates with lentivirus (multiplicity of infection=10:1) (Jikai Gene, Shanghai, China) for 24 hours. The sequence of lentivirus-CASC15 was 5′-GAGCAGATAGCTGAAGAGAGA-3′.

5. Flow cytometry

Digital BD LSR II flow cytometry (BD Biosciences, Franklin Lakes, NJ) was used to evaluate apoptosis and cell cycle progression. Collected cells were mixed with binding buffer and 5 μL fluorescein isothiocyanate-labeled annexin V and 5 μL propidium iodide (BD Biosciences) to examine apoptosis. To evaluate cell cycle progression, we preserved the cells in 75% alcohol for 24 hours and mixed with cell cycle liquid (BD Biosciences).

6. Transwell migration and invasion assays

A Transwell assay (Millipore, Billerica, MA) was performed to evaluate migration and invasion. The upper chamber was filled with 4×10⁴ cells in 200 μL FBS-free medium, and the lower chamber was filled with 700 μL 10% FBS medium. In the invasion assay, 20 μL (1:8, Matrigel:medium) was added to the upper chamber for 30 minutes at 37°C before the experiment. Wright-Giemsa dye (Jiancheng Technology Co., Nanjing, China) was used to stain the cells.

7. 5-Ethynyl-2′-deoxyuridine staining

Cells were cultured in a confocal culture dish for 48 hours, and a 5-ethynyl-2′-deoxyuridine (EdU) DNA Proliferation In Vitro Detection kit (C10310, Ruibo Biological Technology Co.) was used to test cell proliferation. Fluorescence microscopy (Olympus, Tokyo, Japan) was used to observe fluorescence.

8. Cell Counting Kit-8 assay and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

A Cell Counting Kit-8 (CCK-8) Kit (Dojindo, Kumamoto, Japan) was used to detect cell viability. Cells were cultured in 96-well plates (3,000 cells per well). After 0, 24, 48, 72, and 96 hours, we added 100 μL CCK-8 solution and incubated the cells for 3 hours at 37°C. A DYNEX MUM microplate reader (DYNEX Technologies, Chantilly, VA) was used to detect the absorbance at 450 nm. An MTT kit (C11019-2, Ruibo Biological Technology Co.) was used to measure active cells. After 48 hours of incubation of 0, 2, 3, 5, 10, 15, 25, 40, 60, and 100 ng/mL 5-fluorouracil (5-FU), 100 μL MTT solution was incubated with the cells for 4 hours at 37°C. Next, we added 100 μL formazan solving liquid; after 4 hours incubation at 37°C, we detected the absorbance at 570 nm.

9. Fluorescence in situ hybridization and immunofluorescence

Fluorescence in situ hybridization (FISH) and immunofluorescence experiments were carried out to examine the intracellular localization of CASC15 and PRDX2. ICC cells were grown on cover glass and then fixed with 4% paraformaldehyde (with DEPC). Next, probe for CASC15 and antibody for PRDX2 were prepared, with CASC15 marked as red and PRDX2 marked as green. CASC15 probe is 5′-CY3-GCGTGCTTCGGGCAGGGCTACA-3′ and PRDX2 antibody used was the same as western blotting. After hybridization, photos were acquired under a fluorescence microscope.

10. RNA pulldown and RNA immunoprecipitation

RNA pulldown was used to identify the proteins that bind to RNA. We designed RNA probes CASC15-sense-F: TAA-TACGACTCACTATAGGGCAAAAGGGGGAACTCTGA-TG; CASC15-sense-R: CTGTCATCTCTCCCCCACAT; CAS-C15-antisense-F: CAAAAGGGGGAACTCTGATG; and CAS-C15-antisense-R: TAATACGACTCACTATAGGGCTGTCAT-CTCTCCCCCACAT) as complementary strands of sense and antisense CASC15 which were used to mark CASC15. After incubation in cell lysis buffer, RNA-protein complexes were obtained. The complex was separated and resolved with sodium dodecyl sulfate polyacrylamide gel electrophoresis and visualized by silver staining, showing bands at 25–170 kDa. silver staining was performed for detecting whether there were differentially expressed proteins between sense-CASC15 and antisense-CASC15 group. Mass spectrometry was performed to analyze the binding proteins.

RNA immunoprecipitation (RIP) assay was performed to detect the sequence of RNA in the RNA-protein complex. The RIP kit was supplied by Merck (Billerica, MA). We used an antibody for PRDX2 and IgG to detect the specific protein-RNA complex. After splitting the protein, quantitative polymerase chain reaction was conducted to evaluate the RNA sequence.

11. Tumor formation and immunohistochemistry

All studies including animal experiments were approved by the Zhejiang Medical Experimental Animal Care Commission. Twenty male nude mice were provided by the Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province. All nude mice received humane care and our experiments complied with the institution’s guidelines. Transfected cells were collected for subcutaneous injection. We injected 5 million cells into each mouse subcutaneously with 100 μL phosphate-buffered saline into the axillary region. After 1 month, tumor formation was observed. An immunohistochemistry (IHC) assay was performed to stain the monoclonal antibodies for PRDX2, PI3K, AKT, PAKT, and Ki67, the antibodies used were the same as western blotting.

12. Bioinformatic analysis and Statistical analysis

Gene expression Profiling Interactive Analysis (GEPIA) was used for bioinformatic analysis of PRDX2 in ICC, the data source is The Cancer Genome Atlas database (TCGA).

SPSS Statistics ver. 17 software (SPSS Inc., Chicago, IL) was used to perform statistical analysis. Data are presented as the mean±standard deviation. The t test was used to analyze significant differences, and p < 0.05 was considered to indicate a significant difference. The experiments were repeated three times, and error bars represent standard deviation.

Results

1. LncRNA-CASC15 highly expressed in ICC tissues and decreased the overall survival rate

ICC patients from 2013 to 2016 were selected for our study. Ninety-five patients underwent surgery. We collected their tumor tissue and adjacent tissue specimens, extracted the RNA, and detected the relative expression of CASC15. CASC15 was highly expressed in ICC tissues (Fig. 1A). We followed up 81 patients (14 patients were lost to follow-up); 50 patient tumor tissues highly expressed CASC15, while the other 31 patients showed low expression of CASC15. High expression of CASC15 indicated a poor prognosis, and the results were significant (Fig. 1B).

We analyzed the relationship between clinical data and relative CASC15 expression in the 81 patients. We found that CASC15 expression was related to the size of the tumor, Child-Pugh grade, and TNM stage. TNM staging is based on the American Joint Committee on Cancer (AJCC) cancer staging manual (8th edition). However, the difference in the expression of lncRNA-CASC15 was not significantly related to sex, age, α-fetoprotein, carbohydrate antigen 19-9, alanine aminotransferase, hepatitis B surface antigen, liver cirrhosis, vascular invasion, lymphatic metastasis, or distant metastasis (Table 1).

LncRNA-CASC15 was highly expressed in ICC tissues, indicating a larger tumor size, higher risk of surgery, higher tumor malignant degree, and poorer prognosis.

2. Decreased expression of lncRNA-CASC15 influences the function of ICC cells

We detected the relative expression of CASC15 in four types of ICC cells (CCLP, 9810, HuCCT1, and RBE). Next, we selected HuCCT1 and RBE for further experiments (Fig. 1C). We used siRNA-CASC15 to knock down the expression of CASC15 in HuCCT1 and RBE. The knockdown efficiency is good (Fig. 1D).

In the Transwell assay, the migration and invasion of HuCCT1 and RBE cells considerably decreased when CASC15 was knocked down (Fig. 2A and B, S1 Fig.). The EdU experiment showed that the cells were actively proliferating. In HuCCT1 and RBE cells, the EdU-stained cell proportion was significantly decreased in the knockdown group compared to in the control group (Fig. 2C–E). The CCK-8 test showed that cell viability was decreased in the knockdown group at 24, 48, 72, and 96 hours (Fig. 2F and G). Thus, CASC15 facilitated the migration, invasion, and proliferation of ICC cells.

We tested the apoptosis and cell cycle progression of HuCCT1 and RBE cells by flow cytometry. Apoptosis in the knockdown group was significantly increased when compared to the control group. (Fig. 3A and B). Western blotting showed that the expression of proteins relating to apoptosis such as BAX, cleaved PARP, and cleaved caspase-8 were increased in the knockdown group (Fig. 3E, left panel). Knocking down the expression of CASC15 promoted the apoptosis of ICC cells. In the knockdown group, the proportion of cells in G1 phase increased, whereas the proportion of cells in S phase decreased. After knocking down the expression of CASC15, G1/S transition was blocked (Fig. 3C and D). Western blotting showed that the expression of cyclin E1 and cyclin D1, and CDK4, and CDK6 was reduced in the knockdown group (Fig. 3E, right panel). These proteins affect the G1/S transition.

3. LncRNA-CASC15 is bound to protein PRDX2

We performed FISH to detect the location of CASC15 expression in ICC cells. CASC15 was expressed in both the cytoplasm and nucleus (Fig. 4A). RNA pulldown assay and mass spectrometry analysis showed that several proteins bind to CASC15, such as PRDX2, SFN, and ANXA2 (Fig. 4B). The RIP assay further verified that PRDX2 and SFN bound to CASC15 (Fig. 4C).

TCGA revealed that the expression of PRDX2 was associated with disease-free survival of ICC (Fig. 4D). Thus, we chose PRDX2 as the key target protein of CASC15 for further experiments. Western blot analysis showed that the expression of PRDX2 decreased when the expression of CASC15 was knocked down (Fig. 4E). Additionally, FISH showed that the expression locations of PRDX2 and CASC15 were nearly coincident (S2 Fig.). Thus, PRDX2 was related to CASC15 in ICC cells.

4. PRDX2 affects ICC through the PI3K/AKT/c-Myc pathway

We used siRNA-PRDX2-1,2,3 to knock down the expression of PRDX2 in RBE and HUCCT1 cells (Fig. 5A, S3A Fig.). We selected siRNA-1,3 for further experiments. After knocking down PRDX2 expression, the proportion of cells in G1 phase increased, but the proportion of cells in S phase decreased, and western blotting revealed that the expression of cyclin B1 and cyclin D1 was reduced in the knockdown group (Fig. 5B and D, S3B Fig.). The result agreed with the results for CASC15 in ICC cells. In the Transwell invasion experiment, knockdown of PRDX2 expression decreased the number of cells that passed through the Transwell (Fig. 5C, S4A Fig.). The western blot results showed that proteins in endothelial mesenchymal transition (EMT) pathway such as E-cadherin and N-cadherin were altered, as observed in the Transwell assay (Fig. 5D, S3B Fig.).

When PRDX2 expression was knocked down in ICC cells, the IC₅₀ of 5-FU was greatly decreased (S4B Fig.). Compared to the control group, apoptosis in the knockdown group was significantly increased in the presence of 10 ng/mL 5-FU (Fig. 6E and F). Without 5-FU, apoptosis in the knockdown group changed very little (S4C Fig.).

After knocking down the expression of PRDX2 in RBE and HUCCT1 cells, western blot analysis showed that the PI3K/AKT/c-Myc pathway was blocked. Additionally, the protein p21, which regulates the cell cycle, and downstream proteins of the PI3K/AKT pathway were decreased in the knockdown group (Fig. 5E, S3C Fig.).

5. Overexpressed PRDX2 after knocking down the expression of CASC15 rescues the changes

Western blot analysis showed that PI3K/AKT/c-Myc pathway was blocked in the CASC15 knockdown group (Fig. 6A). Overexpressed PRDX2 after knocking down the expression of CASC15 rescued the suppression of the PI3K/AKT pathway (Fig. 6B). Additionally, overexpressed PRDX2 rescued the block of G1/S transition under knockdown of CASC15 (S5 Fig.). Thus, CASC15 functions in ICC possibly through PRDX2.

In the RNA pulldown assay and mass spectrometry analysis, we found that some ubiquitin-related proteins were bound to CASC15. Western blotting showed that the expression of PRDX2 was decreased in the CASC15 knockdown group (Fig. 4E). However, the relative expression of PRDX2 mRNA was only slightly changed (Fig. 6D). The decrease in PRDX2 and block of the PI3K/AKT pathway in the CASC15 knockdown group was rescued by adding MG132 (20 μg/mL for 2 hours) (Fig. 6C). Thus, CASC15 regulates the expression of PRDX2 by inhibiting proteasome formation.

6. Knockout of lncRNA-CASC15 expression suppresses ICC development in vivo

We selected HuCCT1 to carry out lentiviral transfection experiments. After 1 month of subcutaneous injection of cells after transfection, the tumor volume in the control group was 5.47±2.06 cm², and the weight was 5.57±2.10 g. The tumor volume in the knockdown group was 0.37±0.51 cm² (p < 0.001), and the weight was 0.38±0.51 g (p < 0.001). Knockdown of CASC15 decreased the growth of ICC in vivo (Fig. 7A–D).

IHC showed that the expression of PRDX2 decreased in the knockdown group compared to in the control group, which matched the result in cell lines. IHC also showed that PI3K/AKT signaling pathway was inhibited in the knockdown group. CASC15 affected PRDX2 and PI3K/AKT signaling pathway in vivo as well (Fig. 7E).

Discussion

In our study, the expression of CASC15 in ICC tissues was higher than that in para-carcinoma tissues as observed for other tumor promoters, and CASC15 was highly expressed in ICC cell lines such as HuCCT1 and RBE cells. Previous studies showed that CASC15 promotes the progression and metastasis of cancers, indicating a poor prognosis. Based on our analysis of clinical data from patients with ICC, high expression of CASC15 indicated a poor prognosis, larger tumor size, and more advanced stage of TNM, suggesting that CASC15 facilitates the progression of ICC.

In cell functional experiments and animal experiments, we found that knockdown of CASC15 inhibited the proliferation, mitosis, tumor formation, migration, and invasion of ICC cells, while it increased the apoptosis of ICC cells. Knockdown of CASC15 decreased the expression of cyclin E1, cyclin D1, CDK4, and CDK6, inhibited the progression of cell cycle, the mitosis of ICC cells, and the proliferation of ICC cells. Many lncRNAs affect the cell cycle. For example, lncRNA-liver regeneration 1 was found to promote the expression of cyclin D1 by activating Wnt/β-catenin signaling [19]. Knockdown of CASC15 increased the expression of BAX, cleaved PARP, and cleaved caspase-8. Based on our results, lncRNA-CASC15 was involved not only in the death receptor-mediated pathway but also in the mitochondria-mediated pathway. EMT is the epithelial cell transition to mesenchymal cells or fibroblasts, giving cells migration and invasion abilities [20]. LncRNA-HIT [21] and lncRNA-ROR [8] are two lncRNAs involved in the EMT pathway. In the present study, knockdown of CASC15 decreased the expression of N-cadherin and migration and invasion of ICC cells. Thus, knockdown of CASC15 inhibited the migration and invasion of ICC cells.

We confirmed that protein-PRDX2 bound to CASC15 through RNA-pulldown and RIP experiments. Previous studies have shown that PRDX2 is associated with many cancers. Xu et al. [18] confirmed that PRDX2 affects the resistance to 5-FU in colon cancer. In our study, we showed that knockdown of PRDX2 inhibited the invasion of ICC cells, resulting in the block of G1/S transition and increasing the sensitivity to 5-FU. We further confirmed that the function of PRDX2 was linked to the PI3K/AKT/c-Myc signal pathway. A previous report showed that PRDX2 functions by activating PI3K/AKT signaling [18]. Our study clarified that the downstream of PI3K/AKT, c-Myc, was also activated by PRDX2. Furthermore, CASC15 is also an important activity factor of PI3K/AKT/c-Myc. Thus, CASC15 may regulate the function of ICC cells via PI3K/AKT/c-Myc. We showed that CASC15 activated PI3K/AKT through PRDX2 by rescue experiments, indicating that PRDX2 is an important downstream molecule. Some ubiquitination related proteins were found to bind CASC15 in RNA-pulldown experiments. CASC15 may regulate the expression of PRDX2 through the ubiquitination pathway. Although no studies have shown that CASC15 or PRDX2 is related to ubiquitylation, our study confirmed that CASC15 adjusted the expression of PRDX2 through ubiquitylation.

Our study showed that lncRNA-CASC15 was highly expressed in ICC and promoted the development of ICC. However, we did not perform overexpression experiments. We only considered CASC15 knockdown or knockout, and did not confirm that the function of CASC15 was enhanced by overexpression. Additionally, we only evaluated the basic mechanism of CASC15 and its relationship with PRDX2. We found that knockdown of CASC15 decreased the expression of PRDX2 and it was rescued by inhibiting proteasome formation, but we did not evaluate the mechanism or how it bound to the proteasome.

We thought that lncRNA-CASC15 is possibly an oncogenic lncRNA functioning in ICC (Fig. 8). CASC15 is likely to promote the migration, invasion, proliferation, and tumor formation of ICC cells and inhibits the apoptosis of ICC cells. High expression of CASC15 indicates a poor prognosis and high-grade malignancy. CASC15 activates the PI3K/AKT/c-Myc signal pathway possibly by binding to PRDX2 and inhibiting its degradation, resulting in ICC development. Given the role of CASC15 in ICC, lncRNA-CASC15 should be considered as a new promising therapeutic target in ICC therapy.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

crt-2020-192_S1Fig.pdf

crt-2020-192_S2Fig.pdf

crt-2020-192_S3Fig.pdf

crt-2020-192_S4Fig.pdf

crt-2020-192_S5Fig.pdf

NOTES

Ethical Statement

All tissues were obtained with informed consent. The experimental procedure was approved by the Ethics Committee of Zhejiang University.

Author Contributions

Conceived and designed the analysis: Zhang Y, Zhang L, Lu S, Wang W.

Collected the data: Zhang Y, Zhang L, Lu S, Xiang Y, Zeng C, He T.

Contributed data or analysis tools: Zhang Y, Zhang L, Lu S, Xiang Y, Zeng C, He T.

Performed the analysis: Zhang Y.

Wrote the paper: Zhang Y, Zhang L, Lu S, Ding Y, Wang W.

Funding acquisition, project administration: Wang W.

Conflicts of Interest

Conflicts of interest relevant to this article was not reported.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (No. 81572307 and 81773096) and the Major Project of Medical and Health Technology Development Program in Zhejiang Province (No. 7211902).

Fig. 1

Cancer-associated susceptibility 15 (CASC15) affected the prognosis of patients with intrahepatic cholangiocarcinoma (ICC). (A) Relative expression of long non-coding RNA (lncRNA)-CASC15 in tissues of 95 patients. (B) Survival curve analysis of the relationship between lncRNA-CANSC15 expression differences and survival time of patients. (C) Relative expression of ICC cell lines (CCLP, 9810, HuCCT1, and RBE). (D) The efficiency of knockdown of CASC15 in HuCCT1 and RBE cells. **p<0.01, ***p<0.001.

Fig. 2

The knockdown of cancer-associated susceptibility 15 (CASC15) expression inhibited cell invasion and proliferation. (A, B) Transwell invasion experiment and quantitative results. (C–E) EdU experiment showed that cell proliferation capacity was decreased in the siCASC15 group. Scale bars=100 μm. (F, G) Cell Counting Kit-8 (CCK-8) assay showed that the cell proliferation capacity decreased in the siCASC15 group. NC, negative control. **p<0.01, ***p<0.001.

Fig. 3

The knockdown of cancer-associated susceptibility 15 (CASC15) expression promoted cell apoptosis and inhibited G1/S phase transformation. (A, B) Flow cytometry diagram of cell apoptosis and quantitative results. (C, D) Flow cytometry diagram of cell cycle and quantitative results. (E) Western blotting revealed that the expression of apoptosis and cell cycle-related proteins were changed in the siCASC15 group. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NC, negative control; PARP, poly(ADP-ribose) polymerase. *p<0.05, **p<0.01, ***p<0.001.

Fig. 4

Cancer-associated susceptibility 15 (CASC15) was associated with peroxiredoxin 2 (PRDX2) and regulated its expression. (A) Location of CASC15 in intrahepatic cholangiocarcinoma (ICC) cells. (B) RNA-protein complexes were resolved with sodium dodecyl sulfate polyacrylamide gel electrophoresis and visualized by silver staining, showing bands at 25–170 kDa. (C) RNA immunoprecipitation (IP)–quantitative polymerase chain reaction showed PRDX2 bound to CASC15. (D) Relationship of PRDX2 and disease-free survival of patients with ICC in The Cancer Genome Atlas database database. (E) Western blotting revealed that PRDX2 expression was decreased in the siCASC15 group. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NC, negative control. Scale bars=200 μm. **p<0.01, ***p<0.001.

Fig. 5

The knockdown of peroxiredoxin 2 (PRDX2) expression inhibited the invasion and G1/S phase transformation of intrahepatic cholangiocarcinoma (ICC) cells. (A) Efficiency of PRDX2 knockdown in RBE cells. (B) Flow cytometry diagram of cell cycle and quantitative results. (C) Transwell invasion experiment and quantitative results of RBE cells. Scale bars=100 μm. (D) Western blotting showed that the expression levels of cell cycle and endothelial mesenchymal transition (EMT)–related proteins were altered in the siPRDX2 group of RBE cells. (E) Western blotting showed that the phosphoinositide 3-kinase (PI3K)/AKT/c-Myc pathway was inhibited in the siPRDX2 group of RBE cells. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NC, negative control. *p<0.05 and **p<0.01.

Fig. 6

Cancer-associated susceptibility 15 (CASC15) affected phosphoinositide 3-kinase (PI3K)/AKT/c-Myc pathway through peroxiredoxin 2 (PRDX2) and CASC15 regulated PRDX2 by inhibiting ubiquitination. (A) Western blotting showed that the PI3K/AKT/c-Myc pathway was inhibited in the siCASC15 group. (B) Western blotting showed that the PI3K/AKT/c-Myc pathway was enhanced when PRDX2 was overexpressed in the siCASC15 group. (C, D) Expression of PRDX2 was increased and the PI3K/AKT pathway was activated when proteasome formation was inhibited (left panel). Relative expression of PRDX2 changed little in the siCASC15 group (right panel). (E, F) Flow cytometry diagram of cell apoptosis and quantitative results. 5-FU, 5-fluorouracil; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NC, negative control. **p<0.01.

Fig. 7

The knockdown of cancer-associated susceptibility 15 (CASC15) in xenograft model inhibited the development of intrahepatic cholangiocarcinoma (ICC). (A–D) Knockdown of CASC15 in xenograft model decreased tumor size and weight. (E) Immunohistochemistry assay showed peroxiredoxin 2 (PRDX2), phosphoinositide 3-kinase (PI3K), AKT, pAKT, and Ki67 expression levels were decreased in the ShCASC15 group compared to in the control group. NC, negative control. Scale bar=100 μm. **p<0.01.

Fig. 8

Knockdown of cancer-associated susceptibility 15 (CASC-15) inhibits the phosphoinositide 3-kinase (PI3K)/AKT/c-Myc signal pathway possibly by binding to peroxiredoxin 2 (PRDX2) and promoting its degradation, resulting in the decrease of intrahepatic cholangiocarcinoma (ICC) development.

Table 1

Correlation between expression of CASC15 gene and clinical data of ICC

Variable	Low	High	p-value
Sex
Male	17 (56.7)	24 (47.1)	0.492
Female	13 (43.3)	27 (52.9)
Age (yr)
> 50	24 (80.0)	42 (82.4)	0.792
≤ 50	6 (20.0)	9 (17.6)
α-Fetoprotein
> 20	2 (6.7)	0	0.134
≤ 20	28 (93.3)	51 (100)
Carbohydrate antigen 19-9
> 37	21 (70.0)	44 (86.3)	0.076
≤ 37	9 (30.0)	7 (13.7)
Hepatitis B surface antigen
Positive	4 (13.3)	7 (13.7)	0.960
Negative	26 (86.7)	44 (86.3)
Alanine aminotransferase
> 40	11 (36.7)	17 (33.3)	0.761
≤ 40	19 (63.3)	34 (66.7)
Liver cirrhosis
Present	7 (23.3)	16 (31.4)	0.438
Absent	23 (76.7)	35 (68.6)
Vascular invasion
Present	14 (46.7)	30 (58.8)	0.289
Absent	16 (53.3)	21 (41.2)
Lymphatic metastasis
Present	14 (46.7)	25 (49.0)	0.838
Absent	16 (53.3)	26 (51.0)
Child-Pugh
Grade A (5–6)	27 (90.0)	30 (58.8)	0.003
Grade B (7–9)	3 (10.0)	21 (41.2)
Tumor size (cm)
≥ 5	18 (60.0)	42 (82.4)	0.026
< 5	12 (40.0)	9 (17.6)
Distant metastasis
Present	10 (33.3)	14 (27.5)	0.576
Absent	20 (66.7)	37 (72.5)
TNM stage
I–III	17 (56.7)	14 (27.5)	0.009
IV	13 (43.3)	37 (72.5)

Values are presented as number (%). CASC15, cancer-associated susceptibility 15; ICC, intrahepatic cholangiocarcinoma.

REFERENCES

1. Mao K, Jiang W, Liu J, Wang J. Incidence of subsequent cholangiocarcinomas after another malignancy: trends in a population-based study. Medicine (Baltimore). 2015;94:e596.Article PubMed PMC
2. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308–21. Article PubMed PMC
3. Buettner S, van Vugt JL, IJzermans JM, Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 2017;10:1131–42. Article PubMed PMC
4. Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist. 2004;9:43–57. Article
5. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747–53. Article PubMed PMC
6. Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X, et al. Global identification of human transcribed sequences with genome tiling arrays. Science. 2004;306:2242–6. Article PubMed
7. Zhang A, Zhao JC, Kim J, Fong KW, Yang YA, Chakravarti D, et al. LncRNA HOTAIR enhances the androgen-receptor-mediated transcriptional program and drives castration-resistant prostate cancer. Cell Rep. 2015;13:209–21. Article PubMed PMC
8. Gao S, Wang P, Hua Y, Xi H, Meng Z, Liu T, et al. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Oncotarget. 2016;7:1608–18. Article PubMed
9. He T, Zhang L, Kong Y, Huang Y, Zhang Y, Zhou D, et al. Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis. Int J Oncol. 2017;51:1722–30. Article PubMed PMC
10. Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P, et al. A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma. Hepatol Commun. 2018;2:254–69. Article PubMed PMC
11. Jiang F, Ling X. The Advancement of long non-coding RNAs in cholangiocarcinoma development. J Cancer. 2019;10:2407–14. Article PubMed PMC
12. Bertoldi M. Human peroxiredoxins 1 and 2 and their interacting protein partners: through structure toward functions of biological complexes. Protein Pept Lett. 2016;23:69–77. Article PubMed
13. Castaldo SA, Ajime T, Serrao G, Anastacio F, Rosa JT, Giacomantonio CA, et al. Annexin A2 regulates AKT upon H2O2-dependent signaling activation in cancer cells. Cancers (Basel). 2019;11:492.Article PubMed PMC
14. Jin Y, Yang Q, Liang L, Ding L, Liang Y, Zhang D, et al. Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway. J Exp Clin Cancer Res. 2018;37:277.Article PubMed PMC PDF
15. Zhang Y, Sun C, Xiao G, Shan H, Tang L, Yi Y, et al. S-nitrosylation of the peroxiredoxin-2 promotes S-nitrosoglutathione-mediated lung cancer cells apoptosis via AMPK-SIRT1 pathway. Cell Death Dis. 2019;10:329.Article PubMed PMC
16. Luthra S, Chandran U, Diergaarde B, Becich M, Lee AV, Neumann CA. Expression of reactive species related genes is associated with patient survival in luminal B breast cancer. Free Radic Biol Med. 2018;120:170–80. Article PubMed PMC
17. Gu C, Luo J, Lu X, Tang Y, Ma Y, Yun Y, et al. REV7 confers radioresistance of esophagus squamous cell carcinoma by recruiting PRDX2. Cancer Sci. 2019;110:962–72. Article PubMed PMC
18. Xu J, Zhang S, Wang R, Wu X, Zeng L, Fu Z. Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway. Biosci Rep. 2017;37:BSR20160447.Article PubMed PMC PDF
19. Xu D, Yang F, Yuan JH, Zhang L, Bi HS, Zhou CC, et al. Long noncoding RNAs associated with liver regeneration 1 accelerates hepatocyte proliferation during liver regeneration by activating Wnt/beta-catenin signaling. Hepatology. 2013;58:739–51. Article PubMed
20. Togami K, Yamaguchi K, Chono S, Tada H. Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-beta1 in A549, NCI-H441, and Calu-3 cells: development of an in vitro model of respiratory epithelial cells in idiopathic pulmonary fibrosis. J Pharmacol Toxicol Methods. 2017;86:19–27. PubMed
21. Richards EJ, Zhang G, Li ZP, Permuth-Wey J, Challa S, Li Y, et al. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) beta: lncRNA-hit-mediated TGFbeta-induced epithelial to mesenchymal transition in mammary epithelia. J Biol Chem. 2015;290:6857–67. PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Exploring the mechanism of LncRNA CASC15 affecting hepatocellular carcinoma through miRNA
Qingshan Cai, Dongyang Wu, Yueling Shen, Shudong Li, Liyou Liu, Dong Liu, Yong Li, Xiaonan Chen, Limin Wang, Jianxing Zheng
Medicine.2024; 103(5): e35859. CrossRef
The effect of genetics and biochemistry on the pathogenesis of cholangiocarcinoma
Mete Ucdal, Ayse Burus, Basak Celtikci
International Journal of Hepatobiliary and Pancreatic Diseases.2024; 14(2): 1. CrossRef
Interplay between lncRNAs and the PI3K/AKT signaling pathway in the progression of digestive system neoplasms (Review)
Xiaoyu Zhang, Lei Shi, Mengzhen Xing, Chunjing Li, Fengjun Ma, Yuning Ma, Yuxia Ma
International Journal of Molecular Medicine.2024;[Epub] CrossRef
A review on the role of ncRNAs in the pathogenesis of cholangiocarcinoma
Soudeh Ghafouri-Fard, Arash Safarzadeh, Bashdar Mahmud Hussen, Mohammad Taheri, Majid Samsami
International Journal of Biological Macromolecules.2023; 225: 809. CrossRef
A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor
Bin Chang, Zhe Wang, Min Ren, Qianlan Yao, Lu Zhao, Xiaoyan Zhou
International Journal of Gynecological Pathology.2023; 42(5): 451. CrossRef
Development and validation of combined Ki67 status prediction model for intrahepatic cholangiocarcinoma based on clinicoradiological features and MRI radiomics
Xianling Qian, Changwu Zhou, Fang Wang, Xin Lu, Yunfei Zhang, Lei Chen, Mengsu Zeng
La radiologia medica.2023; 128(3): 274. CrossRef
Non-Coding RNA in Cholangiocarcinoma: An Update
Jiehan Li, Haolin Bao, Ziyue Huang, Zixin Liang, Ning Lin, Chunjie Ni, Yi Xu
Frontiers in Bioscience-Landmark.2023;[Epub] CrossRef
A study of the prognostic value of long non-coding RNA CASC15 in human solid tumors utilizing The Cancer Genome Atlas (TCGA) datasets and a meta-analysis
Weiwei Chen, Wenqi Qian, Jun Nie, Mintao Dai
Clinical and Experimental Medicine.2022;[Epub] CrossRef
Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma
Yanhua Wu, Khizar Hayat, Yufei Hu, Jianfeng Yang
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway
Ziyan Chen, Bangjie He, Jungang Zhao, Jiacheng Li, Yifeng Zhu, Leilei Li, Wenming Bao, Jiuyi Zheng, Haitao Yu, Gang Chen
Phytomedicine.2022; 104: 154323. CrossRef
Cystic angiomatosis in children: clinical experience and review of literature
Wen Chao Li, Li Liu, Zhen Dong Wang, Hui Chen, Guang Liu, Zhi Chun Feng
World Journal of Surgical Oncology.2022;[Epub] CrossRef
A Study on Mesoporous Silica Loaded With Novel Photosensitizers HCE6 and Oxaliplatin for the Treatment of Cholangiocarcinoma
Pei-Jian Zhang, Meng-Dong Liu, Fang-Yong Fan, Ke-Xia Liu
Frontiers in Oncology.2021;[Epub] CrossRef
LncRNA CASC15 promotes the proliferation of papillary thyroid carcinoma cells by regulating the miR-7151–5p/WNT7A axis
Dongfang Bai, Chong Guo, Aimin Wang, Guolong Pang, Jing Gao, Chuan Wang, Dapeng Zhao, Jie Yang, Jianmin Ren
Pathology - Research and Practice.2021; 225: 153561. CrossRef
LncRNA CASC15 Promotes Cerebral Ischemia/Reperfusion Injury via miR-338-3p/ETS1 Axis in Acute Ischemic Stroke
Chen Chen, Linjing Wang, Li Wang, Qi Liu, Chunying Wang
International Journal of General Medicine.2021; Volume 14: 6305. CrossRef
Protein profiling reveals potential isomiR-associated cross-talks among RNAs in cholangiocarcinoma
Li Guo, Yuyang Dou, Yifei Yang, Shiqi Zhang, Yihao Kang, Lulu Shen, Lihua Tang, Yaodong Zhang, Changxian Li, Jun Wang, Tingming Liang, Xiangcheng Li
Computational and Structural Biotechnology Journal.2021; 19: 5722. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis

Cancer Res Treat. 2021;53(1):184-198. Published online October 5, 2020

DOI: https://doi.org/10.4143/crt.2020.192

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis

Fig. 1 Cancer-associated susceptibility 15 (CASC15) affected the prognosis of patients with intrahepatic cholangiocarcinoma (ICC). (A) Relative expression of long non-coding RNA (lncRNA)-CASC15 in tissues of 95 patients. (B) Survival curve analysis of the relationship between lncRNA-CANSC15 expression differences and survival time of patients. (C) Relative expression of ICC cell lines (CCLP, 9810, HuCCT1, and RBE). (D) The efficiency of knockdown of CASC15 in HuCCT1 and RBE cells. **p<0.01, ***p<0.001.

Fig. 2 The knockdown of cancer-associated susceptibility 15 (CASC15) expression inhibited cell invasion and proliferation. (A, B) Transwell invasion experiment and quantitative results. (C–E) EdU experiment showed that cell proliferation capacity was decreased in the siCASC15 group. Scale bars=100 μm. (F, G) Cell Counting Kit-8 (CCK-8) assay showed that the cell proliferation capacity decreased in the siCASC15 group. NC, negative control. **p<0.01, ***p<0.001.

Fig. 3 The knockdown of cancer-associated susceptibility 15 (CASC15) expression promoted cell apoptosis and inhibited G1/S phase transformation. (A, B) Flow cytometry diagram of cell apoptosis and quantitative results. (C, D) Flow cytometry diagram of cell cycle and quantitative results. (E) Western blotting revealed that the expression of apoptosis and cell cycle-related proteins were changed in the siCASC15 group. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NC, negative control; PARP, poly(ADP-ribose) polymerase. *p<0.05, **p<0.01, ***p<0.001.

Fig. 4 Cancer-associated susceptibility 15 (CASC15) was associated with peroxiredoxin 2 (PRDX2) and regulated its expression. (A) Location of CASC15 in intrahepatic cholangiocarcinoma (ICC) cells. (B) RNA-protein complexes were resolved with sodium dodecyl sulfate polyacrylamide gel electrophoresis and visualized by silver staining, showing bands at 25–170 kDa. (C) RNA immunoprecipitation (IP)–quantitative polymerase chain reaction showed PRDX2 bound to CASC15. (D) Relationship of PRDX2 and disease-free survival of patients with ICC in The Cancer Genome Atlas database database. (E) Western blotting revealed that PRDX2 expression was decreased in the siCASC15 group. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NC, negative control. Scale bars=200 μm. **p<0.01, ***p<0.001.

Fig. 5 The knockdown of peroxiredoxin 2 (PRDX2) expression inhibited the invasion and G1/S phase transformation of intrahepatic cholangiocarcinoma (ICC) cells. (A) Efficiency of PRDX2 knockdown in RBE cells. (B) Flow cytometry diagram of cell cycle and quantitative results. (C) Transwell invasion experiment and quantitative results of RBE cells. Scale bars=100 μm. (D) Western blotting showed that the expression levels of cell cycle and endothelial mesenchymal transition (EMT)–related proteins were altered in the siPRDX2 group of RBE cells. (E) Western blotting showed that the phosphoinositide 3-kinase (PI3K)/AKT/c-Myc pathway was inhibited in the siPRDX2 group of RBE cells. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NC, negative control. *p<0.05 and **p<0.01.

Fig. 6 Cancer-associated susceptibility 15 (CASC15) affected phosphoinositide 3-kinase (PI3K)/AKT/c-Myc pathway through peroxiredoxin 2 (PRDX2) and CASC15 regulated PRDX2 by inhibiting ubiquitination. (A) Western blotting showed that the PI3K/AKT/c-Myc pathway was inhibited in the siCASC15 group. (B) Western blotting showed that the PI3K/AKT/c-Myc pathway was enhanced when PRDX2 was overexpressed in the siCASC15 group. (C, D) Expression of PRDX2 was increased and the PI3K/AKT pathway was activated when proteasome formation was inhibited (left panel). Relative expression of PRDX2 changed little in the siCASC15 group (right panel). (E, F) Flow cytometry diagram of cell apoptosis and quantitative results. 5-FU, 5-fluorouracil; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NC, negative control. **p<0.01.

Fig. 7 The knockdown of cancer-associated susceptibility 15 (CASC15) in xenograft model inhibited the development of intrahepatic cholangiocarcinoma (ICC). (A–D) Knockdown of CASC15 in xenograft model decreased tumor size and weight. (E) Immunohistochemistry assay showed peroxiredoxin 2 (PRDX2), phosphoinositide 3-kinase (PI3K), AKT, pAKT, and Ki67 expression levels were decreased in the ShCASC15 group compared to in the control group. NC, negative control. Scale bar=100 μm. **p<0.01.

Fig. 8 Knockdown of cancer-associated susceptibility 15 (CASC-15) inhibits the phosphoinositide 3-kinase (PI3K)/AKT/c-Myc signal pathway possibly by binding to peroxiredoxin 2 (PRDX2) and promoting its degradation, resulting in the decrease of intrahepatic cholangiocarcinoma (ICC) development.

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

Fig. 7

Fig. 8

Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis

Table 1

Correlation between expression of CASC15 gene and clinical data of ICC

Variable	Low	High	p-value
Sex
Male	17 (56.7)	24 (47.1)	0.492
Female	13 (43.3)	27 (52.9)
Age (yr)
> 50	24 (80.0)	42 (82.4)	0.792
≤ 50	6 (20.0)	9 (17.6)
α-Fetoprotein
> 20	2 (6.7)	0	0.134
≤ 20	28 (93.3)	51 (100)
Carbohydrate antigen 19-9
> 37	21 (70.0)	44 (86.3)	0.076
≤ 37	9 (30.0)	7 (13.7)
Hepatitis B surface antigen
Positive	4 (13.3)	7 (13.7)	0.960
Negative	26 (86.7)	44 (86.3)
Alanine aminotransferase
> 40	11 (36.7)	17 (33.3)	0.761
≤ 40	19 (63.3)	34 (66.7)
Liver cirrhosis
Present	7 (23.3)	16 (31.4)	0.438
Absent	23 (76.7)	35 (68.6)
Vascular invasion
Present	14 (46.7)	30 (58.8)	0.289
Absent	16 (53.3)	21 (41.2)
Lymphatic metastasis
Present	14 (46.7)	25 (49.0)	0.838
Absent	16 (53.3)	26 (51.0)
Child-Pugh
Grade A (5–6)	27 (90.0)	30 (58.8)	0.003
Grade B (7–9)	3 (10.0)	21 (41.2)
Tumor size (cm)
≥ 5	18 (60.0)	42 (82.4)	0.026
< 5	12 (40.0)	9 (17.6)
Distant metastasis
Present	10 (33.3)	14 (27.5)	0.576
Absent	20 (66.7)	37 (72.5)
TNM stage
I–III	17 (56.7)	14 (27.5)	0.009
IV	13 (43.3)	37 (72.5)

Values are presented as number (%). CASC15, cancer-associated susceptibility 15; ICC, intrahepatic cholangiocarcinoma.

Table 1 Correlation between expression of CASC15 gene and clinical data of ICC

Values are presented as number (%). CASC15, cancer-associated susceptibility 15; ICC, intrahepatic cholangiocarcinoma.